tiprankstipranks
PepGen Inc. (PEPG)
NASDAQ:PEPG
US Market
PEPG
PepGen Inc.
RESEARCH TOOLSreports
Want to see PEPG full AI Analyst Report?

PepGen Inc. (PEPG) Earnings Dates, Call Summary & Reports

280 Followers

Earnings Data

Report Date
Aug 06, 2026
Before Open (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.28
Last Year’s EPS
-0.7
Same Quarter Last Year
Analyst Consensus
Moderate Buy
Based on 5 Analysts Ratings

Earnings Call Summary

Q4 2023
Earnings Call Date:Mar 06, 2024|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and a strong financial position due to recent funding, as well as regulatory advancements such as FDA fast track designation. However, there were challenges with increased expenses and a notable net loss for the year. Despite these financial lowlights, the clinical and regulatory achievements present a strong positive outlook.
Company Guidance
During the PepGen Q4 2023 earnings call, the company provided guidance on several key metrics and developments. They highlighted the initiation of clinical trials for their EDO cell-penetrating peptide platform targeting Duchenne Muscular Dystrophy (DMD) and myotonic dystrophy type 1 (DM1). PepGen's lead program, PGN-EDO51, aims to treat DMD with an exon 51-skipping approach, targeting approximately 13% of DMD patients in the U.S. and EU. They completed enrollment for cohort 1 in CONNECT1-EDO51 at a 5 mg per kg dose and anticipate escalating to 10 mg per kg pending safety reviews. The company expects preliminary data for the 5 mg per kg cohort by mid-2024, with projections suggesting high dystrophin production levels. For DM1, the FDA lifted a clinical hold on EDODM1, which received fast track designation. The FREEDOM-DM1 Phase I trial began dosing in December 2023, and PepGen aims to report preliminary data in the second half of 2024. Financially, PepGen reported a net loss of $19.5 million for Q4 and $78.6 million for the full year, with research and development expenses totaling $68.1 million in 2023. Following a stock offering in early 2024, they are positioned to fund operations into 2026.
Clinical Trial Progress
Completed enrollment for cohort 1 in CONNECT1-EDO51 evaluating 5 mg per kg dose in DMD patients in the Phase II clinical trial. Clearance received from MHRA in the U.K. to initiate CONNECT2-EDO51, a Phase II study of EDO51.
Financial Position
Successful underwritten stock offering raised approximately $80 million, extending projected cash runway into 2026.
FDA Fast Track Designation
EDODM1 granted fast track designation by FDA, facilitating development and review of therapies for serious conditions with unmet medical needs.
Dystrophin Production Expectations
At 10 mg per kg dose cohort, potential to achieve greater than 9% of normal levels of dystrophin protein, highest level achieved by a DMD exon-skipping therapy to date.

PepGen Inc. (PEPG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

PEPG Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 06, 2026
2026 (Q2)
-0.28 / -
-0.7―――
May 12, 2026
2026 (Q1)
-0.29 / -0.26
-0.9271.74% (+0.66)――
Mar 04, 2026
2025 (Q4)
-0.35 / -0.27
-0.6860.29% (+0.41)――
Nov 12, 2025
2025 (Q3)
-0.56 / -0.52
-0.6621.21% (+0.14)――
Aug 07, 2025
2025 (Q2)
-0.85 / -0.70
-0.8719.54% (+0.17)――
May 08, 2025
2025 (Q1)
-0.72 / -0.92
-0.627-46.73% (-0.29)――
Feb 24, 2025
2024 (Q4)
-0.81 / -0.68
-0.81316.36% (+0.13)――
Nov 07, 2024
2024 (Q3)
-0.87 / -0.66
-0.9832.65% (+0.32)――
Aug 08, 2024
2024 (Q2)
-0.72 / -0.87
-0.82-6.10% (-0.05)――
May 14, 2024
2024 (Q1)
-0.69 / -0.63
-0.699.13% (+0.06)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

PEPG Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 12, 2026
$1.68$1.78+5.95%
Mar 04, 2026
$6.76$5.50-18.57%
Nov 12, 2025
$4.65$5.13+10.32%
Aug 07, 2025
$1.37$1.19-13.14%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does PepGen Inc. (PEPG) report earnings?
PepGen Inc. (PEPG) is schdueled to report earning on Aug 06, 2026, Before Open (Confirmed).
    What is PepGen Inc. (PEPG) earnings time?
    PepGen Inc. (PEPG) earnings time is at Aug 06, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is PEPG EPS forecast?
          PEPG EPS forecast for the fiscal quarter 2026 (Q2) is -0.28.